More and more common antibiotics are losing their effectiveness because they are used too often, allowing bacteria to develop resistance to the drugs. A University of Rhode Island researcher has found a solution to this problem with a natural compound that boosts antibiotic strength from 100 to 1,000 times.
While conducting research on infection prevention, URI microbiology professor Paul Cohen stumbled upon a compound -- lysophosphatidic acid -- that is naturally produced in the human body in great quantities wherever there is inflammation.
According to Cohen, bacteria are divided into two groups -- gram-positive and gram-negative -- based on the structure of their cell walls. When lysophosphatidic acid is administered in small amounts (80 micromolars), it sensitizes the gram-negative bacteria 100 to 1,000 times, so only small quantities of antibiotics are needed to kill the bacteria. When administered to fight gram-positive bacteria, the compound kills the bacteria without needing any antibiotics.
In combination with this compound, even older antibiotics become much more powerful, Cohen said. It not only makes older antibiotics useful again, but it also allows them to be used in reduced dosages.
Lysophosphatidic acid is currently available commercially as a powder for researchers. Cohen holds a patent on its use with antibiotics. He said it can be formulated for a variety of applications, depending on where the infection is found.
For cystic fibrosis patients, for instance, who often suffer from lung infections, it can be formulated for use as an inhalant. Burn patients or those with acne can use it as a lotion to rub on the skin. It can be applied in many ways, said the Narragansett resident who worked on the project with URI professor David Laux, former URI technician Maryjane Utley and Danish researcher Karen Krogfelt of the Statenserum Institut in Copenhagen.
Cohen said that since the compound is naturally found in the bloodstream, it is non-toxic and patients should not be allergic to it. We know it works in the test tube, he said, but we still need to show that it works on animals. Im sure that for surface diseases like acne, doctors would use it right away.
Cohen is seeking pharmaceutical-based partners to invest in the project and fund the next stage of research to bring this discovery to market.
Source: University of Rhode Island
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.